Company / Shareholders' Equity
Verrica Pharmaceuticals Inc. Shareholders' Equity History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
-$9.9M
FY2025
5-year range
-$9.9M / $40.0M
FY2021-FY2025
Trend
-149.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Verrica Pharmaceuticals Inc. reports negative total equity of -$10M in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-$10M in FY2025.
Declined from $40M to -$10M over the past 2 years.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, shareholders' equity decreased 149.9% year-over-year.
- Peak shareholders' equity was recorded in FY2023.
Company context
Key Data Points
- Altman Z-Score -3.86 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$9.9M | -149.9% |
| FY2024 | $19.8M | -50.6% |
| FY2023 | $40.0M | +22.8% |
| FY2022 | $32.6M | -1.2% |
| FY2021 | $33.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026